Noteworthy Price Action: What’s Ahead for Balchem Corporation After Touching 52-Week High?

Noteworthy Price Action: What's Ahead for Balchem Corporation After Touching 52 Week High?

The stock of Balchem Corporation (NASDAQ:BCPC) hit a new 52-week high and has $84.05 target or 5.00% above today’s $80.05 share price. The 7 months bullish chart indicates low risk for the $2.59 billion company. The 1-year high was reported on Dec, 1 by Barchart.com. If the $84.05 price target is reached, the company will be worth $129.50 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 47,452 shares traded hands. Balchem Corporation (NASDAQ:BCPC) has risen 28.85% since April 28, 2016 and is uptrending. It has outperformed by 22.92% the S&P500.

Analysts await Balchem Corporation (NASDAQ:BCPC) to report earnings on March, 6.

Balchem Corporation (NASDAQ:BCPC) Ratings Coverage

Out of 2 analysts covering Balchem (NASDAQ:BCPC), 0 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 0 are positive. Balchem has been the topic of 2 analyst reports since March 8, 2016 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Tuesday, March 8 by Sidoti. Pivotal Research downgraded Balchem Corporation (NASDAQ:BCPC) on Friday, November 4 to “Sell” rating.

According to Zacks Investment Research, “Balchem Corporation is engaged in the development, manufacture and marketing of specialty performance ingredients for the food, feed and medical sterilization industries. They operate in two business segments, the micro-encapsulation of performance ingredients and the repackaging and marketing of high quality specialty gases. They sell their products through their own sales force, independent distributors and sales agents.”

Insitutional Activity: The institutional sentiment decreased to 1.21 in Q2 2016. Its down 0.01, from 1.22 in 2016Q1. The ratio fall, as 11 funds sold all Balchem Corporation shares owned while 54 reduced positions. 14 funds bought stakes while 65 increased positions. They now own 24.68 million shares or 4.84% less from 25.93 million shares in 2016Q1.
Blackrock Advisors Ltd Liability Corp holds 0% of its portfolio in Balchem Corporation (NASDAQ:BCPC) for 14,863 shares. Voya Mgmt Ltd has 13,626 shares for 0% of their US portfolio. Massmutual Trust Fsb Adv holds 0% of its portfolio in Balchem Corporation (NASDAQ:BCPC) for 300 shares. Price T Rowe Assoc Incorporated Md accumulated 0% or 10,830 shares. Avalon Advisors Ltd Limited Liability Company owns 26,830 shares or 0.06% of their US portfolio. Segall Bryant Hamill Limited Liability Company holds 0.64% of its portfolio in Balchem Corporation (NASDAQ:BCPC) for 406,908 shares. Profund Advsr Ltd Liability Co last reported 0.01% of its portfolio in the stock. Deutsche Bank Ag has 0% invested in the company for 39,115 shares. Fin Professionals holds 0% or 122 shares in its portfolio. Us National Bank & Trust De has 0% invested in the company for 5,605 shares. Renaissance Technologies Ltd, a New York-based fund reported 10,600 shares. Moreover, Loring Wolcott Coolidge Fiduciary Advisors Llp Ma has 0.02% invested in Balchem Corporation (NASDAQ:BCPC) for 17,655 shares. Stephens Invest Mngmt Gru Limited Liability Corp accumulated 363,754 shares or 0.71% of the stock. Mondrian Inv Partners Limited, a United Kingdom-based fund reported 64,863 shares. Century Capital Mgmt Llc accumulated 0.46% or 70,521 shares.

Insider Transactions: Since July 13, 2016, the stock had 0 insider purchases, and 8 insider sales for $6.99 million net activity. ROSSI DINO A had sold 16,400 shares worth $1.12M on Thursday, September 8. $104,619 worth of Balchem Corporation (NASDAQ:BCPC) shares were sold by MCMILLAN EDWARD. $271,320 worth of shares were sold by Houston Matthew David on Tuesday, September 20. Backus William A. sold $823,680 worth of stock.

More notable recent Balchem Corporation (NASDAQ:BCPC) news were published by: Fool.com which released: “Balchem Corporation Sees Steady Health and Nutrition Growth” on November 08, 2016, also Fool.com with their article: “Balchem Corporation Sees a Bright Future in Human Nutrition Markets” published on August 11, 2016, Marketwatch.com published: “Balchem Corp. NASDAQ: BCPC” on October 18, 2010. More interesting news about Balchem Corporation (NASDAQ:BCPC) were released by: Quotes.Wsj.com and their article: “News Balchem Corp.BCPC” published on February 12, 2011 as well as Fool.com‘s news article titled: “Balchem Corporation Revenue Drops on Weak Energy Demand” with publication date: February 29, 2016.

BCPC Company Profile

Balchem Corporation (Balchem), incorporated on January 30, 1967, is engaged in the development, manufacture, distribution and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical and medical sterilization industries. The Firm operates in four divisions: SensoryEffects, Animal Nutrition & Health (ANH), Specialty Products and Industrial Products. The Firm sells its products through its own sales force, independent distributors and sales agents. The Company’s SensoryEffects segment provides creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, chocolate systems, ice cream bases and variegates, ready-to-eat cereals, grain snacks and cereal ingredients. ANH segment provides basic choline chloride, and microencapsulation and chelation technologies nutritional products. Specialty Products segment provides ethylene oxide and propylene oxide products. The Company’s Industrial Products segment provides Choline Chloride and methylamines. The Company’s subsidiaries include SensoryEffects, Inc. (SE), SensoryEffects Cereal Systems, Inc. (SECS), BCP Ingredients, Inc. (BCP) and Aberco, Inc. (Aberco).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment